Aurora sets out to capitalize on FDA’s new framework for bespoke drug therapies

Co-founded by Jennifer Doudna and Fyodor Urnov, the company intends to simultaneously develop many gene editing treatments for rare conditions by using the agency’s “plausible mechanism” pathway.